Randomized Controlled Trial
doi: 10.1002/mds.20666.
Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease
Affiliations
- PMID: 16142776
- DOI: 10.1002/mds.20666
Item in Clipboard
Randomized Controlled Trial
Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease
Mov Disord.
2006 Jan.
Abstract
We performed a double-blind randomized placebo-controlled pilot study to determine the efficacy of tegaserod (Zelnorm) in treating constipation in 15 patients with Parkinson's disease (PD). There was a trend for improvement in the Subject's Global Assessment (SGA) of satisfaction with bowel habits (NS) and the total SGA (including abdominal discomfort, bothersome constipation, and satisfaction; NS).
Copyright (c) 2005 Movement Disorder Society.
Similar articles
-
Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study.Am J Gastroenterol. 2005 Feb;100(2):362-72. doi: 10.1111/j.1572-0241.2005.40749.x. Am J Gastroenterol. 2005. PMID: 15667494 Clinical Trial.
-
Review article: tegaserod for chronic constipation.Aliment Pharmacol Ther. 2004 Nov;20 Suppl 7:20-4. doi: 10.1111/j.1365-2036.2004.02187.x. Aliment Pharmacol Ther. 2004. PMID: 15521851 Review.
-
Safety, tolerability, and efficacy of tegaserod over 13 months in patients with chronic constipation.Am J Gastroenterol. 2006 Nov;101(11):2558-69; quiz 2671. doi: 10.1111/j.1572-0241.2006.00789.x. Am J Gastroenterol. 2006. PMID: 17090282 Clinical Trial.
-
A randomized, multicenter comparison of polyethylene glycol laxative and tegaserod in treatment of patients with chronic constipation.Am J Gastroenterol. 2007 Sep;102(9):1964-71. doi: 10.1111/j.1572-0241.2007.01365.x. Epub 2007 Jun 15. Am J Gastroenterol. 2007. PMID: 17573794 Clinical Trial.
-
Tegaserod for constipation-predominant irritable bowel syndrome.Pharmacotherapy. 2007 Feb;27(2):267-77. doi: 10.1592/phco.27.2.267. Pharmacotherapy. 2007. PMID: 17253916 Review.
Cited by
-
Bladder and bowel dysfunction in Parkinson's disease.J Neural Transm (Vienna). 2008;115(3):443-60. doi: 10.1007/s00702-007-0855-9. Epub 2008 Mar 10. J Neural Transm (Vienna). 2008. PMID: 18327532 Review.
-
Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies.Mov Disord. 2018 Mar;33(3):372-390. doi: 10.1002/mds.27344. Mov Disord. 2018. PMID: 29508455 Free PMC article. Review.
-
Management of faecal incontinence and constipation in adults with central neurological diseases.Cochrane Database Syst Rev. 2014 Jan 13;2014(1):CD002115. doi: 10.1002/14651858.CD002115.pub5. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2024 Oct 29;10:CD002115. doi: 10.1002/14651858.CD002115.pub6. PMID: 24420006 Free PMC article. Updated.
-
Bladder, bowel, and sexual dysfunction in Parkinson's disease.Parkinsons Dis. 2011;2011:924605. doi: 10.4061/2011/924605. Epub 2011 Sep 12. Parkinsons Dis. 2011. PMID: 21918729 Free PMC article.
-
Dopamine-induced nonmotor symptoms of Parkinson's disease.Parkinsons Dis. 2011;2011:485063. doi: 10.4061/2011/485063. Epub 2011 Apr 11. Parkinsons Dis. 2011. PMID: 21603184 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
